Center for Immunobiology and Vaccine Development, University of California-San Francisco (UCSF) Benioff Children's Hospital, Oakland.
Department of Pediatrics, School of Medicine, UCSF, San Francisco.
J Infect Dis. 2019 Mar 15;219(7):1130-1137. doi: 10.1093/infdis/jiy609.
Meningococcal outer membrane vesicle (OMV) vaccines are prepared with detergents to remove endotoxin, which also remove desirable antigens such as factor H binding protein (FHbp). Native OMV (NOMV) vaccines with genetically attenuated endotoxin do not require detergent treatment and elicit broader serum bactericidal antibody (SBA) responses than OMV or recombinant FHbp (rFHbp) vaccines.
We measured human complement-mediated SBA responses in mice immunized with NOMV with overexpressed FHbp subfamily B (NOMV-FHbp), NOMV with FHbp genetically inactivated (NOMV-KO), and/or a control rFHbp vaccine against meningococcal and gonococcal strains.
Despite having 36-fold less FHbp per dose, the NOMV-FHbp vaccine elicited a ≥3-fold higher serum IgG anti-FHbp geometric mean titer than control vaccines containing rFHbp (P ≤ .003). Against 2 meningococcal outbreak strains with mismatched PorA and heterologous FHbp subfamily B sequence variants, the NOMV-FHbp vaccine produced ≥30-fold higher SBA titers than control vaccines. Mice immunized with NOMV-FHbp and NOMV-KO vaccines also elicited SBA against a gonococcal strain (P < .0001 vs the adjuvant-only control group). In contrast, 2 licensed meningococcal serogroup B vaccines, including one containing detergent-extracted OMV, did not produce gonococcal SBA in humans.
A meningococcal NOMV vaccine elicits SBA against gonococci and with overexpressed FHbp elicits SBA against meningococci.
脑膜炎球菌外膜囊泡(OMV)疫苗用去污剂制备以去除内毒素,这也去除了诸如因子 H 结合蛋白(FHbp)等理想的抗原。具有遗传减毒内毒素的天然 OMV(NOMV)疫苗不需要去污剂处理,并且比 OMV 或重组 FHbp(rFHbp)疫苗引起更广泛的血清杀菌抗体(SBA)反应。
我们在接种 NOMV 过表达 FHbp 亚家族 B(NOMV-FHbp)、FHbp 遗传失活的 NOMV(NOMV-KO)和/或对照 rFHbp 疫苗的小鼠中测量了人补体介导的 SBA 反应针对脑膜炎球菌和淋病奈瑟菌株。
尽管 NOMV-FHbp 疫苗每剂量的 FHbp 含量低 36 倍,但血清 IgG 抗-FHbp 几何平均滴度比含有 rFHbp 的对照疫苗高 3 倍以上(P ≤.003)。针对 2 种带有 PorA 错配和异源 FHbp 亚家族 B 序列变体的脑膜炎球菌暴发株,NOMV-FHbp 疫苗产生的 SBA 滴度比对照疫苗高 30 倍以上。接种 NOMV-FHbp 和 NOMV-KO 疫苗的小鼠也对淋病奈瑟菌株产生了 SBA(P <.0001 与仅佐剂对照组相比)。相比之下,2 种已许可的脑膜炎球菌 B 群疫苗,包括一种含有去污剂提取的 OMV,在人类中未产生淋病奈瑟菌 SBA。
脑膜炎球菌 NOMV 疫苗可诱导针对淋病奈瑟菌的 SBA,而过表达 FHbp 的 NOMV 疫苗可诱导针对脑膜炎球菌的 SBA。